Across TCGA pan-cancer cohorts, KRTAP10-6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KRTAP10-6 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher KRTAP10-6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP10-6 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, ESCA, and LUAD are the cancer types where KRTAP10-6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.197	0.622	<.001	42	view →
ESCA	DFS	Median	All	0.080	0.533	<.001	18	view →
LUAD	DFS	Median	IV	0.045	0.717	<.001	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.309	.026	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: KRTAP10-6 tumor-vs-normal RNA expression · all KRTAP10-6 data types